Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 7/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 6/20 | 0.41 |
| ▸ | FLT3 | P36888 | 5/20 | 0.41 |
| ▸ | GAS6 | Q14393 | 5/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482035 | 1.00 | MERTK (0.41) | MERTKTYRO3FLT3GAS6CHUK | |
| SCHEMBL15204665 | 0.92 | ADORA2A (0.42) | MERTKTYRO3FLT3GAS6ADORA2A | |
| SCHEMBL481581 | 0.84 | JAK1 (0.42) | MERTKTYRO3FLT3GAS6CCNT1 | |
| SCHEMBL481582 | 0.84 | JAK1 (0.42) | MERTKTYRO3FLT3GAS6CCNT1 | |
| SCHEMBL15003312 | 0.83 | MERTK (0.39) | MERTKTYRO3FLT3GAS6MAPK8 | |
| SCHEMBL482124 | 0.82 | BTK (0.45) | MAPK8BTK | |
| SCHEMBL482125 | 0.82 | BTK (0.45) | MAPK8BTK | |
| SCHEMBL12069879 | 0.81 | PDE10A (0.47) | CCNT1BTKADORA2A | |
| SCHEMBL2210308 | 0.81 | MAPK8 (0.44) | MAPK8MAPK9ADORA2A | |
| SCHEMBL2210310 | 0.81 | MAPK8 (0.44) | MAPK8MAPK9ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457913-B1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2090577-B1 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2671876-A2 | Pyrazine derivatives and their use as protein kinase inhbitors | Akinion Pharmaceuticals AB (SE) | 2013-12-11 | — | — | EP | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-8436171-B2 | Amino substituted pyrazines as inhibitors or protein kinases | AKINION PHARMACEUTICALS AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-8372976-B2 | Methods of treatment comprising the administration of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2457913-A2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2078016-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | disclosed |
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
| EP-2252597-A2 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | Akinion Pharmaceuticals AB (SE) | 2010-11-24 | — | — | EP | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095399-A2 | PYRAZINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHBITORS | AKINION PHARMACEUTICALS AB (SE) | 2009-08-06 | — | — | WO | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | MERTK 46/4885TYRO3 43/4885FLT3 1/4885 |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | MERTK 46/4885TYRO3 43/4885FLT3 1/4885 |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | MERTK 747/4885TYRO3 362/4885FLT3 239/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | MERTK 823/4885TYRO3 319/4885FLT3 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.